NYSE:JNJ - New York Stock Exchange, Inc. - US4781601046 - Common Stock - Currency: USD
162.3
+2.62 (+1.64%)
The current stock price of JNJ is 162.3 USD. In the past month the price increased by 10.68%. In the past year, price increased by 0.28%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B | ||
RPRX | ROYALTY PHARMA PLC- CL A | 8.15 | 19.69B |
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 131,900 full-time employees. The firm's primary focus is products related to human health and well-being. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY 08933 US
CEO: A. Gorsky
Employees: 131900
Company Website: https://www.jnj.com/
Investor Relations: https://www.investor.jnj.com
Phone: 17325242455
The current stock price of JNJ is 162.3 USD. The price increased by 1.64% in the last trading session.
The exchange symbol of JOHNSON & JOHNSON is JNJ and it is listed on the New York Stock Exchange, Inc. exchange.
JNJ stock is listed on the New York Stock Exchange, Inc. exchange.
28 analysts have analysed JNJ and the average price target is 173.33 USD. This implies a price increase of 6.79% is expected in the next year compared to the current price of 162.3. Check the JOHNSON & JOHNSON stock analysts ratings, price target forecast and up-and down grades for more detailed information.
JOHNSON & JOHNSON (JNJ) has a market capitalization of 390.76B USD. This makes JNJ a Mega Cap stock.
JOHNSON & JOHNSON (JNJ) currently has 131900 employees.
JOHNSON & JOHNSON (JNJ) has a support level at 162.08 and a resistance level at 164.14. Check the full technical report for a detailed analysis of JNJ support and resistance levels.
The Revenue of JOHNSON & JOHNSON (JNJ) is expected to grow by 1.16% in the next year. Check the estimates tab for more information on the JNJ EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
JOHNSON & JOHNSON (JNJ) has a dividend yield of 3.15%. The yearly dividend amount is currently 4.46. Check the full fundamental report for a detailed analysis of JNJ dividend history, reliability and sustainability.
JOHNSON & JOHNSON (JNJ) will report earnings on 2025-04-15, before the market open.
The PE ratio for JOHNSON & JOHNSON (JNJ) is 16.25. This is based on the reported non-GAAP earnings per share of 9.99 and the current share price of 162.3 USD. Check the full fundamental report for a full analysis of the valuation metrics for JNJ.
The outstanding short interest for JOHNSON & JOHNSON (JNJ) is 0.78% of its float. Check the ownership tab for more information on the JNJ short interest.
ChartMill assigns a technical rating of 7 / 10 to JNJ. When comparing the yearly performance of all stocks, JNJ turns out to be only a medium performer in the overall market: it outperformed 54.8% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to JNJ. JNJ scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months JNJ reported a non-GAAP Earnings per Share(EPS) of 9.99. The EPS decreased by -4.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 16.74% | ||
ROA | 8.24% | ||
ROE | 20.93% | ||
Debt/Equity | 0.47 |
ChartMill assigns a Buy % Consensus number of 74% to JNJ. The Buy consensus is the average rating of analysts ratings from 28 analysts.
For the next year, analysts expect an EPS growth of 6.82% and a revenue growth 1.16% for JNJ